Comparison

Claude Science vs GPT-Rosalind vs Isomorphic Labs

The life-science efforts of Anthropic, OpenAI and Alphabet compared as of November 2026: what each one is, who can use it, named partners, stated focus and how close each is to a clinical trial.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 13, 2026

The Short Version

These three are often grouped together and are different kinds of thing. Claude Science is a workbench application that scientists run with Anthropic's general models. GPT-Rosalind is a specialised model from OpenAI that approved organisations can call. Isomorphic Labs is an Alphabet drug company that keeps its design engine in house and earns money from partnerships and, eventually, its own medicines. As of November 13, 2026, none of the three has a drug in a registered human trial under its own name.

Side by Side

Claude ScienceGPT-RosalindIsomorphic Labs
CompanyAnthropicOpenAIIsomorphic Labs, an Alphabet company spun out of Google DeepMind
What it isA research workbench applicationA reasoning model for life sciencesA drug discovery company with a proprietary design engine, IsoDDE
LaunchedBeta on June 30, 2026Research preview on April 16, 2026. Left preview September 11, 2026Founded 2021. IsoDDE described in February 2026
Who can use itPaid Claude plans, per launch coverageEligible organisations approved through a trusted-access programmeNot offered as a product. Used internally and with partners
How it is usedRuns on Linux, macOS or a remote machine, with more than 60 built-in skills and connectorsIn ChatGPT Enterprise, Codex and the API, for approved internal researchIsomorphic's own scientists design molecules for its programmes and its partners' targets
Named pharma and biotech partnersBristol Myers Squibb, Novo Nordisk, BigHat Biosciences, Divergence Labs, Enveda, Generate Biomedicines, The Column GroupNovo Nordisk, Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, UCSF School of PharmacyEli Lilly, Novartis, Johnson & Johnson
Published deal valuesNoneNoneLilly: $45M upfront, up to $1.7B in milestones. Novartis: $37.5M upfront, up to $1.2B. Johnson & Johnson: not disclosed
Own drug programmesYes, preclinical. Two rare forms of muscular dystrophy, through the acquisition of Mithril MedicineNone announcedYes, partnered and wholly owned. No candidate named
Clinical statusNo trial. Anthropic says one could start as soon as late 2028 if candidates hold upNot applicableNo registered trial found. Company target is a first trial by the end of 2026
Funding specific to this effortNot disclosedNot disclosed$2.1B Series B in May 2026, after $600M in 2025

Stated Focus

EffortWhat the company says it is for
Claude ScienceBringing separate research tools, databases and analysis into one workspace. Coverage lists genomics, proteomics, structural biology and cheminformatics
GPT-RosalindBiology, drug discovery and translational medicine: evidence synthesis, hypothesis generation, experiment planning and multi-step research tasks
Isomorphic LabsDesigning drugs directly. Its engine covers small molecules, antibodies, peptides and molecular glues, according to its Johnson & Johnson announcement

Claude Science

Anthropic released Claude Science in beta on June 30, 2026, and at the same event said it would start its own drug discovery programmes for neglected diseases. On October 27 it reported early laboratory and document-review results from six partners and disclosed that it had acquired Mithril Medicine. Anthropic describes the work as early and mostly preclinical. Details and dates are on the Anthropic life sciences partnerships page.

GPT-Rosalind

OpenAI introduced GPT-Rosalind on April 16, 2026, two days after announcing its partnership with Novo Nordisk. Access began with qualified enterprise customers in the United States. Organisations must show legitimate research use, governance controls and restricted access. On September 11 OpenAI said the model was leaving research preview and was available to eligible organisations worldwide. Third-party trackers list API pricing of $5 per million input tokens and $25 per million output tokens from October 5, 2026. OpenAI also released a free life sciences plugin for Codex that connects to more than 50 public databases and works with its standard models.

On benchmarks, OpenAI reported a score of 0.751 on the public BixBench bioinformatics test against 0.732 for GPT-5.4, and said GPT-Rosalind beat GPT-5.4 on 6 of 11 LABBench2 tasks. These are OpenAI's own figures. See OpenAI and Novo Nordisk for the partnership.

Isomorphic Labs

Isomorphic does not sell access to its engine. It is paid through upfront fees, funded research, milestones and royalties from drugmakers, and is building its own pipeline. Its chief executive said in January 2026 that it expects its first clinical trials by the end of 2026, a year later than an earlier target. On November 13, 2026, ClinicalTrials.gov showed no study sponsored by the company. Details are on the Isomorphic Labs funding and clinical trial status page.

How to Think About the Difference

  • Tool or drug company. Anthropic and OpenAI mainly sell software that other people's scientists use. Isomorphic designs the molecules itself.
  • Who carries the drug risk. With Claude Science and GPT-Rosalind, the customer does. Isomorphic shares it, which is why its deals have milestone payments. See biobucks.
  • Overlap is allowed. Novo Nordisk works with both OpenAI and Anthropic. Eli Lilly works with Isomorphic and has a separate lab with Nvidia.
  • None is proven in patients. Compounds from other AI drug companies are further along. See AI-designed drugs in clinical trials.

Sources

Anthropic: its October 27, 2026 post, with Pharmaceutical Technology and The Decoder for the launch. OpenAI: The Decoder and AI Catchup, since OpenAI's own page blocked our reader. Isomorphic: its Series B release, its Johnson & Johnson announcement and Reuters via Investing.com. Presenc AI has not tested any of the three. Status as of November 13, 2026.

Frequently Asked Questions

Claude Science is a workbench application from Anthropic, released in beta on June 30, 2026, that runs research workflows using Claude models. GPT-Rosalind is a specialised life-sciences model from OpenAI, introduced April 16, 2026, that approved organisations access through ChatGPT Enterprise, Codex and the API.
No. Access is through an OpenAI trusted-access programme for eligible organisations, which must show legitimate research use and governance controls. It began with enterprise customers in the United States and was extended worldwide on September 11, 2026.
No. Isomorphic Labs is a drug discovery company. Its design engine, IsoDDE, is proprietary and used by its own scientists and with partners Eli Lilly, Novartis and Johnson & Johnson.
None, as of November 13, 2026. Isomorphic Labs targets a first trial by the end of 2026. Anthropic says its own programmes could reach trials as soon as late 2028 if candidates hold up. OpenAI has not announced drug programmes of its own.
Third-party pricing trackers list $5 per million input tokens and $25 per million output tokens on the API from October 5, 2026. We could not open OpenAI's own pricing page to confirm. Usage during the research preview was not charged, according to launch coverage.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access